Terminally differentiated skeletal myotubes are not confined to G0 but can enter G1 upon growth factor stimulation.
Terminally differentiated cells are specialized cells unable to proliferate that constitute most of the mammalian body. Despite their abundance, little information exists on the characteristics of cell cycle control in these cells and the molecular mechanisms that prevent their proliferation. They are generally believed to be irreversibly restricted to the G0 state. In this report, we define some features of a paradigmatic terminally differentiated system, the skeletal muscle, by studying its responses to various mitogenic stimuli. We show that forced expression of a number of cell cycle-regulatory genes, including erbB-2, v-ras, v-myc, B-myb, ld-1, and E2F-1, alone or in combinations, cannot induce terminally differentiated skeletal muscle cells (myotubes) to synthesize DNA. However, serum-stimulated myotubes display a typical immediate-early response, including the up-regulation of c-fos, c-jun, c-myc, and ld-1. They also elevate the expression of cyclin D1 after 4 hours of serum treatment. All these events take place in myotubes in a way that is indistinguishable from that of quiescent, undifferentiated myoblasts reactivated by serum. Moreover, pretreatment with serum shortens the time required by E1A to induce DNA synthesis, confirming that myotubes can partially traverse G1. Serum growth factors do not activate late-G1 genes in myotubes, suggesting that the block that prevents terminally differentiated cells from proliferating acts in mid-G1. Our results show that terminally differentiated cells are not confined to G0 but can partially reenter G1 in response to growth factors; they contribute to a much-needed definition of terminal differentiation. The important differences in the control of the cell cycle between terminally differentiated and senescent cells are discussed.
Tiainen
M
M
Molecular Oncogenesis Laboratory Regina Elena Cancer Center, Rome, Italy.
Pajalunga
D
D
Ferrantelli
F
F
Soddu
S
S
Salvatori
G
G
Sacchi
A
A
Crescenzi
M
M
D017500:Adenovirus E1A Proteins / Q000235:genetics; D000818:Animals; D015152:Blotting, Northern; D015153:Blotting, Western; D018797:Cell Cycle Proteins / Q000096:biosynthesis / Q000235:genetics; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis / Q000235:genetics; D016193:G1 Phase / Q000187:drug effects / Q000235:genetics; D006133:Growth Substances / Q000494:pharmacology*; D018257:Helix-Loop-Helix Motifs / Q000235:genetics; D051798:Inhibitor of Differentiation Protein 1; D051379:Mice; D018482:Muscle, Skeletal / Q000166:cytology* / Q000187:drug effects; D009857:Oncogenes / Q000235:genetics; D012313:RNA / Q000032:analysis; D011993:Recombinant Fusion Proteins; D012097:Repressor Proteins; D016192:Resting Phase, Cell Cycle / Q000187:drug effects / Q000235:genetics; D016196:S Phase / Q000187:drug effects / Q000235:genetics; D013997:Time Factors; D014157:Transcription Factors / Q000096:biosynthesis / Q000235:genetics; D014162:Transfection
D017500:Adenovirus E1A Proteins; D018797:Cell Cycle Proteins; D006133:Growth Substances; C497455:Idb1 protein, mouse; D051798:Inhibitor of Differentiation Protein 1; D011993:Recombinant Fusion Proteins; D012097:Repressor Proteins; D014157:Transcription Factors; D012313:RNA; D004247:DNA